Macrophage-activation syndrome

WikiDoc Resources for Macrophage-activation syndrome

Articles

Most recent articles on Macrophage-activation syndrome

Most cited articles on Macrophage-activation syndrome

Review articles on Macrophage-activation syndrome

Articles on Macrophage-activation syndrome in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Macrophage-activation syndrome

Images of Macrophage-activation syndrome

Photos of Macrophage-activation syndrome

Podcasts & MP3s on Macrophage-activation syndrome

Videos on Macrophage-activation syndrome

Evidence Based Medicine

Cochrane Collaboration on Macrophage-activation syndrome

Bandolier on Macrophage-activation syndrome

TRIP on Macrophage-activation syndrome

Clinical Trials

Ongoing Trials on Macrophage-activation syndrome at Clinical Trials.gov

Trial results on Macrophage-activation syndrome

Clinical Trials on Macrophage-activation syndrome at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Macrophage-activation syndrome

NICE Guidance on Macrophage-activation syndrome

NHS PRODIGY Guidance

FDA on Macrophage-activation syndrome

CDC on Macrophage-activation syndrome

Books

Books on Macrophage-activation syndrome

News

Macrophage-activation syndrome in the news

Be alerted to news on Macrophage-activation syndrome

News trends on Macrophage-activation syndrome

Commentary

Blogs on Macrophage-activation syndrome

Definitions

Definitions of Macrophage-activation syndrome

Patient Resources / Community

Patient resources on Macrophage-activation syndrome

Discussion groups on Macrophage-activation syndrome

Patient Handouts on Macrophage-activation syndrome

Directions to Hospitals Treating Macrophage-activation syndrome

Risk calculators and risk factors for Macrophage-activation syndrome

Healthcare Provider Resources

Symptoms of Macrophage-activation syndrome

Causes & Risk Factors for Macrophage-activation syndrome

Diagnostic studies for Macrophage-activation syndrome

Treatment of Macrophage-activation syndrome

Continuing Medical Education (CME)

CME Programs on Macrophage-activation syndrome

International

Macrophage-activation syndrome en Espanol

Macrophage-activation syndrome en Francais

Business

Macrophage-activation syndrome in the Marketplace

Patents on Macrophage-activation syndrome

Experimental / Informatics

List of terms related to Macrophage-activation syndrome

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Synonyms and keywords: MAS

## Overview[edit | edit source]

Macrophage-activation syndrome (MAS) is a severe, potentially life-threatening, complication of several chronic rheumatic diseases of childhood. It occurs most commonly with systemic-onset juvenile idiopathic arthritis (SoJIA), which is also known as Still's disease. In addition, MAS has been described in association with systemic lupus erythematosus (SLE), Kawasaki disease, and adult-onset Still's disease. It is thought to be closely related and pathophysiologically very similar to reactive (secondary) hemophagocytic lymphohistiocytosis (HLH). The incidence of MAS is unknown as there is a wide spectrum of clinical manifestations, and episodes may remain unrecognized.

## Pathophysiology[edit | edit source]

In many cases a trigger is identified, often a viral infection, or a medication. There is uncontrolled activation and proliferation of macrophages, and T lymphocytes, with a marked increase in circulating cytokines, such as IFN-gamma, and GM-CSF. The underlying causative event is unclear, and is the subject of ongoing research. In many cases of MAS, a decreased natural killer cell (NK-cell) function is found.

## Causes[edit | edit source]

### Drug side effect[edit | edit source]

* Canakinumab

## Diagnosis[edit | edit source]

The hallmark clinical and laboratory features include high fever, hepatosplenomegaly, lymphadenopathy, pancytopenia, liver dysfunction, disseminated intravascular coagulation, hypofibrinogenemia, hyperferritinemia, and hypertriglyceridemia. Despite marked systemic inflammation, the erythrocyte sedimentation rate (ESR) is paradoxically depressed, caused by low fibrinogen levels. The low ESR helps to distinguish the disorder from a flare of the underlying rheumatic disorder, in which case the ESR is usually elevated. A bone marrow biopsy or aspirate usually shows hemophagocytosis.

The diagnosis relies on the findings outlined above. In addition, other specific markers of macrophage activation (e.g. soluble CD63), and lymphocyte activation (e.g. soluble IL-2 receptor) can be helpful. NK cell function analysis may show depressed NK function, or, flow cytometry may show a depressed NK cell population.

## Treatment[edit | edit source]

The best treatment for MAS has not been firmly established. Most commonly used treatments include high-dose glucocorticoids, and cyclosporine. In refractory cases treatment regimens are used similar to that in HLH.

## References[edit | edit source]

Template:WH Template:WikiDoc Sources